Stockscreener 앱 받기
14.05
4.29%
-0.63
시간 외 거래:
13.89
-0.16
-1.14%
전일 마감가:
$14.68
열려 있는:
$14.13
하루 거래량:
1.83M
Relative Volume:
0.69
시가총액:
$2.00B
수익:
-
순이익/손실:
$-412.89M
주가수익비율:
-3.6399
EPS:
-3.86
순현금흐름:
$-361.93M
1주 성능:
+7.58%
1개월 성능:
+5.80%
6개월 성능:
+101.29%
1년 성능:
-56.85%
1일 변동 폭
$13.75
$14.29
1주일 범위
$12.43
$15.22
52주 변동 폭
$6.36
$35.90
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
DYN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
14.05 | 2.09B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-25 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 개시 | Bernstein | Mkt Perform |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Dyne Therapeutics (DYN) Sees Downgrade by Oppenheimer | DYN Stoc - GuruFocus
Dyne Therapeutics (DYN) Is Up 17.0% After Positive One-Year ACHIEVE Trial Data for Z-Basivarsen – Has The Bull Case Changed? - Yahoo Finance
Heatmap analysis for Dyne Therapeutics Inc. and competitorsJuly 2025 Weekly Recap & Reliable Volume Spike Trade Alerts - newser.com
Signal strength of Dyne Therapeutics Inc. stock in tech scannersMarket Volume Summary & Stock Portfolio Risk Management - newser.com
Will Dyne Therapeutics Inc. stock keep outperforming rivalsMarket Weekly Review & Daily Growth Stock Investment Tips - newser.com
What moving averages say about Dyne Therapeutics Inc.2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
Can Dyne Therapeutics Inc. stock hit analyst price targets2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Dyne Therapeutics (NASDAQ:DYN) - MarketBeat
What machine learning models say about Dyne Therapeutics Inc.2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Is Dyne Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Rallies & AI Driven Stock Reports - newser.com
Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026 - Seeking Alpha
Stocks With Rising Relative Price Strength: Dyne Therapeutics - Investor's Business Daily
Dyne Therapeutics Inc. (DYN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts - ts2.tech
Dyne Therapeutics (NASDAQ:DYN) Trading Up 10.8%Here's Why - MarketBeat
Dyne Therapeutics rises on positive data from myotonic dystrophy trial - Seeking Alpha
Dyne Therapeutics (DYN) Reports Encouraging Phase 1/2 Trial Resu - GuruFocus
Dyne Therapeutics Reports Strength, Function Improvement From Myotonic Dystrophy Drug Candidate in Ongoing Early Phase Trial - MarketScreener
What drives Dyne Therapeutics Inc stock priceTechnical Pattern Recognition & Free Exceptional ROI Methods - earlytimes.in
Dyne Therapeutics, Inc. Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 - MarketScreener
Dyne Therapeutics reports positive one-year data for DM1 treatment By Investing.com - Investing.com Nigeria
Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.7%Here's Why - MarketBeat
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen for Myotonic Dystrophy Type 1 - Investing News Network
Dyne Therapeutics reports positive one-year data for DM1 treatment - Investing.com
Dyne Therapeutics Reports Significant One-Year Clinical Data for Zeleciment Basivarsen in Patients with Myotonic Dystrophy Type 1 - Quiver Quantitative
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - The Manila Times
Dyne Therapeutics Reports 1-Year Functional Gains at 6.8 mg/kg | DYN Stock News - Stock Titan
Applying big data sentiment scoring on Dyne Therapeutics Inc.2025 Buyback Activity & Daily Profit Focused Screening - newser.com
Applying Elliott Wave Theory to Dyne Therapeutics Inc.Market Risk Summary & Capital Protection Trade Alerts - newser.com
Technical signs of recovery in Dyne Therapeutics Inc.Quarterly Portfolio Report & AI Powered Market Entry Strategies - newser.com
Using Python tools to backtest Dyne Therapeutics Inc. strategiesPortfolio Performance Summary & Fast Moving Trade Plans - newser.com
What risks investors should watch in Dyne Therapeutics Inc. stock2025 Bull vs Bear & Technical Pattern Based Buy Signals - newser.com
Dyne Therapeutics Inc. stock momentum explainedJuly 2025 Outlook & Growth Oriented Trade Recommendations - newser.com
Dyne’s Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data - Insider Monkey
Dyne Therapeutics Elects Brian Posner to Board - The Globe and Mail
Dyne Therapeutics' Valuation Leaves No Room For Error (NASDAQ:DYN) - Seeking Alpha
How Dyne Therapeutics Inc. stock performs in high volatility markets2025 Technical Overview & Real-Time Stock Movement Alerts - newser.com
Does Dyne Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Trends & AI Driven Price Forecasts - newser.com
Will Dyne Therapeutics Inc. stock sustain high P E ratiosEarnings Recap Summary & Consistent Profit Trading Strategies - newser.com
Dyne Therapeutics Appoints Brian Posner to its Board of Directors - GlobeNewswire
Dyne Therapeutics appoints Brian Posner to board of directors By Investing.com - Investing.com Nigeria
Dyne Therapeutics Appoints Brian Posner to Board of Directors - Quiver Quantitative
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
다인 테라 주식 (DYN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 04 '25 |
Sale |
13.27 |
894 |
11,863 |
95,017 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 05 '25 |
Sale |
13.41 |
144 |
1,931 |
94,873 |
| Kerr Douglas | Chief Medical Officer |
Sep 04 '25 |
Sale |
13.27 |
3,552 |
47,135 |
89,263 |
| Kerr Douglas | Chief Medical Officer |
Sep 05 '25 |
Sale |
13.41 |
873 |
11,707 |
88,390 |
5.74%
자본화:
|
볼륨(24시간):